Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Psychopharmacology Bulletin · 2026
DOI: 10.64719/pb.16572 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Psychopharmacology Bulletin, 2026. Verfasst von Muneeb Ahmad Muneer und 12 weiteren Autor:innen. Beteiligte Einrichtung: Muneer, MBBS, Allama Iqbal Medical College, Lahore, Punjab, Pakistan. Hauptthemen laut MEDLINE: Bipolar Disorder, Dibenzocycloheptenes, Antipsychotic Agents. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Objective
To provide an updated evaluation of the efficacy and safety of asenapine in bipolar disorder using evidence from randomized controlled trials.
Methods
An updated systematic review and pairwise meta-analysis was conducted in accordance with PRISMA guidelines. PubMed, Embase, Scopus, and ClinicalTrials.gov were searched from inception to October 2025. Randomized controlled trials comparing asenapine with placebo were included. The primary outcome was change from baseline in Young Mania Rating Scale (YMRS) scores. Secondary outcomes included Clinical Global Impressions–Bipolar Severity (CGI-BP-S) overall and mania scores, Montgomery–Åsberg Depression Rating Scale (MADRS) scores, and incidence of adverse events. Random-effects models with restricted maximum-likelihood estimation and Hartung–Knapp adjustment were applied.
Results
Five trials comprising 1,593 participants were included. Asenapine significantly reduced manic symptoms compared with placebo (YMRS mean difference −4.00, 95% CI −5.55 to −2.45). Significant improvements were observed in CGI-BP-S overall severity (−0.51, 95% CI −0.78 to −0.24) and mania scores (−0.47, 95% CI −0.77 to −0.16). modest improvement was observed in MADRS scores (−1.38, 95% CI −2.52 to −0.24). Adverse events were more frequent with asenapine.
Conclusion
Asenapine is an effective short-term treatment for acute mania in bipolar disorder, with tolerability considerations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Muneer, MBBS, Allama Iqbal Medical College, Lahore, Punjab, Pakistan.
- Hafsa, Karachi Medical and Dental College, Karachi, Sindh, Pakistan.
- Ahmed, Second Affiliated Hospital of Kunming Medical University, Kunming City, Yunnan, China.
- Mahmood, Aga Khan University Hospital, Karachi, Sindh, Pakistan. ORCID: 0009-0007-8513-9587.
- Khalid, Rawalpindi Medical University, Rawalpindi, Punjab, Pakistan.
- Ali, Wah Medical College, Wah Cantonment, Punjab, Pakistan. ORCID: 0009-0004-9067-4873.
Zitieren
APA
Muneer, M. A., Hafsa, Ahmed, U., Mahmood, A., Khalid, M., Ali, Z., Shafee, W. F., Ali Khan, S., Nasir, H., Farrukh, M. K., Khansa, U., Azam Raja, H. A., & Haider, S. T. (2026). Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Psychopharmacology Bulletin. https://doi.org/10.64719/pb.16572
Vancouver
Muneer MA, Hafsa, Ahmed U, Mahmood A, Khalid M, Ali Z, et al. Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Psychopharmacology Bulletin. 2026. doi:10.64719/pb.16572
BibTeX
@article{Muneer2026,
author = {Muneer, Muneeb Ahmad and Hafsa and Ahmed, Umair and Mahmood, Abdullah and Khalid, Moneeba and Ali, Zain and Shafee, Warda Fatima and Ali Khan, Suboor and Nasir, Hanana and Farrukh, Muhammad Khubair and Khansa, Ume and Azam Raja, Hafsa Arshad and Haider, Syed Tehseen},
title = {Efficacy and Safety of Asenapine in Bipolar Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Psychopharmacology Bulletin},
year = {2026},
doi = {10.64719/pb.16572}
}
EUVIMED